T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.

doi:10.1016/j.ymthe.2026.03.012

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Jul 2026

Xu Xiongfei, Gu Haihui, Cha Zhanshan, Zhang Bin, Yuan Shuai, Ding Xiuwen, Gao Lei, Gao Suizhi, Wu Xinqian, Gu Lingyun, Huang Jianye, Hao Jianling, Li Penghao, Li Yikai, Kang Xiaochao, Shi Xiaohan, Yin Xiaoyi, Wang Huan, Li Bo, Shi Meilong, Jing Wei, Zheng Kailian, Zheng Chunhong, Shih Yi-Ping, Wu Cong, Zheng Chenggang, Qian Baohua, Tang Gusheng, Yang Jianmin, Guo Shiwei, Tran Eric, Jin Gang

Abstract excerpt

Adoptive T cell transfer targeting KRAS G12D can induce tumor regression in advanced epithelial cancers. The safety, efficacy of T cell receptor (TCR)-T cells targeting KRAS G12V, and potential benefit of repeat infusions remain unknown. In a single-arm phase 1/2 clinical trial (NCT04146298), we treated five patients with recurrent pancreatic cancer using adoptive transfer of autologous T cells engineered to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Neoplasm Staging

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocytes

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41814655
DOI: 10.1016/j.ymthe.2026.03.012
PMCID: PMC13330042

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.PMID 41814655Read ↗

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationSemantic proximity Read ↗

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.Semantic proximity Read ↗

Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutationsSemantic proximity Read ↗

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerSemantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read ↗

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read ↗

More T cell receptors to the RAScue in cancer?Semantic proximity Read ↗

Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.Semantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read ↗

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.